Brief: Synact Pharma Q3 Loss After Tax At SEK 23.9 Mln

SynAct Pharma AB

04/11/2022 06:05

Nov 4 (Reuters) - SynAct Pharma AB  SYNACT.ST :
    * SYNACT PHARMA PUBLISHES Q3 2022 INTERIM REPORT
    * Q3 LOSS AFTER TAX AMOUNTED TO SEK 23,919 (18,222) THOUSAND
    * Q3 PROFIT AFTER TAX IS IMPROVED BY EFFECT THAT ARISES
BECAUSE OF
DANISH TAX CREDIT SCHEME

Source text for Eikon:  ID:nMFN4cqj9h 
Further company coverage:  SYNACT.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))